A detailed history of Bank Of Nova Scotia transactions in United Therapeutics Corp stock. As of the latest transaction made, Bank Of Nova Scotia holds 3,137 shares of UTHR stock, worth $1.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,137
Previous 2,358 33.04%
Holding current value
$1.14 Million
Previous $751,000 49.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$311.04 - $363.55 $242,300 - $283,205
779 Added 33.04%
3,137 $1.12 Million
Q2 2024

Aug 14, 2024

SELL
$228.26 - $319.04 $15.8 Million - $22.1 Million
-69,280 Reduced 96.71%
2,358 $751,000
Q1 2024

May 14, 2024

BUY
$210.76 - $249.51 $9.85 Million - $11.7 Million
46,759 Added 187.95%
71,638 $16.5 Million
Q4 2023

Feb 12, 2024

BUY
$214.88 - $256.94 $4.69 Million - $5.61 Million
21,822 Added 713.84%
24,879 $5.47 Million
Q3 2023

Nov 14, 2023

SELL
$211.82 - $248.24 $222,834 - $261,148
-1,052 Reduced 25.6%
3,057 $690,000
Q2 2023

Aug 03, 2023

SELL
$205.19 - $232.99 $46,167 - $52,422
-225 Reduced 5.19%
4,109 $907,000
Q1 2023

May 11, 2023

BUY
$212.99 - $276.17 $923,098 - $1.2 Million
4,334 New
4,334 $970,000
Q2 2022

Aug 05, 2022

SELL
$174.81 - $241.14 $20.2 Million - $27.8 Million
-115,371 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$166.16 - $213.96 $18.4 Million - $23.6 Million
110,452 Added 2245.42%
115,371 $20.7 Million
Q4 2021

Feb 11, 2022

SELL
$184.32 - $216.08 $31.8 Million - $37.2 Million
-172,277 Reduced 97.22%
4,919 $1.06 Million
Q3 2021

Nov 12, 2021

BUY
$179.86 - $214.88 $31.4 Million - $37.5 Million
174,351 Added 6128.33%
177,196 $32.7 Million
Q2 2021

Aug 12, 2021

BUY
$170.47 - $211.93 $484,987 - $602,940
2,845 New
2,845 $510,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.5B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Bank Of Nova Scotia Portfolio

Follow Bank Of Nova Scotia and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Nova Scotia with notifications on news.